Search results
Results from the WOW.Com Content Network
Patented Medicine Prices Review Board office in Ottawa. Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.
In Canada, the medication pricing is overseen by the Patented Medicine Prices Review Board (PMPRB), which monitors the prices set for patented drugs. [62] One way the PMPRB evaluates whether drug pricing by patentees is excessive by considering international drug pricing. [63] The PMPRB also compares the price of the drug to a similar market. [64]
1 Main Discussion of the PMPRB Article. 5 comments. ... 3 Patented Medicine Prices Review Board. 4 Not Much of An Article, Is It? 5 Administrators: Do NOT Delete.
In Canada, the Patented Medicine Prices Review Board (PMPRB) determines a maximum price for all drugs. In 1987, Bill C-22 established an extended period of protection for patents prior to licensing, which would allow for generics to enter the market.
For premium support please call: 800-290-4726 more ways to reach us
For example, in the UK the Pharmaceutical Price Regulation Scheme is intended to ensure that the National Health Service is able to purchase drugs at "reasonable prices". In Canada, the Patented Medicine Prices Review Board examines drug pricing, compares the proposed Canadian price to that of seven other countries and determines if a price is ...
In Canada, the Patented Medicine Prices Review Board examines drug pricing and determines if a price is excessive or not. In these circumstances, drug manufacturers must submit a proposed price to the appropriate regulatory agency.
A portion of the disclosure of this patent document contains material which is subject to (copyright or mask work) protection. The (copyright or mask work) owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but ...